Alpine Associates Management’s Cidara Therapeutics CDTX Stock Holding History

Alpine Associates Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-208,560	Closed	-$46.1M	–	76
2025 Q4	$46.1M	Buy	+208,560	New	+$33.7M	3.06%	11

Alpine Associates Management's CDTX Position: Q1 2026 in Review

Alpine Associates Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 208,560 shares — an estimated $46.1M sold.

Alpine Associates Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $46.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Alpine Associates Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Alpine Associates Management sold 208,560 Cidara Therapeutics shares in Q1 2026, an estimated $46.1M.
Alpine Associates Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Alpine Associates Management's Cidara Therapeutics position peaked at $46.1M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Alpine Associates Management's 13F filing for Q1 2026, filed 21 Apr 2026.